Arterial Occlusive Disease | Inflammatory Cytokines and Atherosclerotic Plaque Progression. Therapeutic Implications | springermedicine.com

Springer Medicine

Top

Current Atherosclerosis Reports

Published in:

Open Access 01-12-2020 | Arterial Occlusive Disease | Vascular Biology (J Hamilton, Section Editor)

Inflammatory Cytokines and Atherosclerotic Plaque Progression. Therapeutic Implications

Author: Antonio V Sterpetti

Published in: Current Atherosclerosis Reports | Issue 12/2020

Login to get access

Abstract

Purpose of the Review

Inflammatory cytokines play a major role in atherosclerotic plaque progression. This review summarizes the rationale for personalized anti-inflammatory therapy.

Recent Findings

Systemic inflammatory parameters may be used to follow the clinical outcome in primary and secondary prevention. Medical therapy, both in patients with stable cardiovascular disease, or with acute events, may be tailored taking into consideration the level and course of systemic inflammatory mediators. There is significant space for improvement in primary prevention and in the treatment of patients who have suffered from severe cardiovascular events, paying attention to not only blood pressure and cholesterol levels but also including inflammatory parameters in our clinical analysis.

Summary

The potential exists to alter the course of atherosclerosis with anti-inflammatory drugs. With increased understanding of the specific mechanisms that regulate the relationship between inflammation and atherosclerosis, new, more effective and specific anti-inflammatory treatment may become available.

1.

Roth GA, Forouzanfar MH, Moran AE, Barber R, Nguyen G, Feigin VL, et al. Demographic and epidemiologic drivers of global cardiovascular mortality. N Engl J Med. 2015;372:1333–41. https://doi.org/10.1056/NEJMoa1406656.CrossRefPubMed

2.

Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics–2018 update: a report from the American Heart Association. Circulation. 2018;137:e67–e492. https://doi.org/10.1161/CIR.0000000000000558.CrossRefPubMed

3.

Ross R. The pathogenesis of atherosclerosis--an update. N Engl J Med. 1986;314:488–500.CrossRefPubMed

4.

• Tabas I. 2016 Russell Ross Memorial Lecture in Vascular Biology: molecular-cellular mechanisms in the progression of atherosclerosis. Arterioscler Thromb Vasc Biol. 2017;37(2):183–9. https://doi.org/10.1161/ATVBAHA.116.308036. The paper describes the fundamental contribution of Dr Russell Ross in identifying the basic mechanisms for the development of the atherosclerotic plaque, including characterization of Platelet Derived Growth Factor.

5.

Libby P, Bornfeldt KE. Tall AR Atherosclerosis: successes, surprises and future challenges. Circ Res. 2016;118:531–4. https://doi.org/10.1161/CIRCRESAHA.116.308334.CrossRefPubMed

6.

Geng Y-J, Libby P. Evidence for apoptosis in advanced human atheroma. Colocalization with interleukin-1b-converting enzyme. Am J Pathol. 1995;147:251–66.PubMed

7.

Amento EP, Ehsani N, Palmer H, Libby P. Cytokines and growth factors positively and negatively regulate intersitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1991;11:1223–30.CrossRef

8.

• Pasterkamp G, den Ruijter HM, Libby P. Temporal shifts in clinical presentation and underlying mechanisms of atherosclerotic disease. Nat Rev Cardiol. 2017;14:21–9. The Authors describe the possible changes in the pathology of the coronary artery plaques. These changes alter the stability of the plaque with the risk of consequent clinical events.

9.

Gimbrone MA, García-Cardeña G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. An up-to-date summary of the roles of endothelial cells in atherosclerosis from a pioneering investigator. Circ Res. 2016;118:620–36.CrossRefPubMed

10.

Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res. 2016;118:547–63.CrossRefPubMed

11.

• Boren J, Williams KJ. The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity. Curr Opin Lipidol. 2016;27:473–83. A careful description of the role of Low Density Lipoproteins in the formation and progression of the atherosclerotic plaque.

12.

Liuzzo G, Biasucci LM, Gallimore RL, Grillo RL, Rebuzzi AG, Maseri A, et al. The prognostic value of C-protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 1994;331:417–24.CrossRefPubMed

13.

Libby P, Hansson GK, Lichtman AH. Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity. 2013;38:1092–104.CrossRefPubMed

14.

Libby P, Nahrendorf M, Swirski FK. Leukocytes link local and systemic inflammation in ischemic cardiovascular disease. J Am Coll Cardiol. 2016;67:1091–103.CrossRefPubMed

15.

Ahmadi A, Leipsic J, Blankstein R, Taylor C, Hecht H, Stone GW, et al. Do plaques rapidly progress prior to myocardial infarction? The interplay between plaque vulnerability and progression. Circ Res. 2015;117:99–104. https://doi.org/10.1161/CIRCRESAHA.117.305637.

16.

van Dijk RA, Duinisveld AJ, Schaapherder AF, Mulder-Stapel A, Hamming JF, Kuiper J, et al. A change in inflammatory footprint precedes plaque instability: a systematic evaluation of cellular aspects of the adaptive immune response in human atherosclerosis. J Am Heart Assoc. 2015; e 001403. https://doi.org/10.1161/JAHA.114.001403.

17.

Crea F, Libby P. Pathogenesis of acute coronary syndrome. J Am Coll Cardiol. 2013;61:1–11.CrossRefPubMed

18.

Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the unstable plaque. Prog Cardiovasc Dis. 2002;44:349–56.CrossRefPubMed

19.

Libby P, Hansson GK, Lichtman AH. Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity. 2013;38:1092–104.CrossRefPubMed

20.

Libby P. Inflammation and atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32:2045–51. https://doi.org/10.1161/ATVBAHA.108.179705.CrossRefPubMed

21.

Hansson GK. Libby P The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006;6:508–19.CrossRefPubMed

22.

Libby P, Pasterkamp G, Crea F, Jang IK. Reassessing the mechanisms of acute coronary syndromes. Circ Res. 2019;124(1):150–60. https://doi.org/10.1161/CIRCRESAHA.118.311098.CrossRefPubMed

23.

Ketelhuth DF, Hansson GK. Adaptive response of T and B cells in atherosclerosis. Circ Res. 2016;118:668–78.CrossRef

24.

Maier A, Wu H, Cordasic N, Oefner P, Dietel B, Thiele C, et al. Hypoxia-inducible protein 2 Hig2/Hilpda mediates neutral lipid accumulation in macrophages and contributes to atherosclerosis in apolipoprotein E-deficient mice. FASEB J. 2017;31:4971–84. https://doi.org/10.1096/fj.201700235R.

25.

Van der Veken B, De Meyer GRY, Martinet W. Axitinib attenuates intraplaque angiogenesis, haemorrhages and plaque destabilization in mice. Vasc Pharmacol. 2018;100:34–40. https://doi.org/10.1016/j.vph.2017.10.004.CrossRef

26.

Ginhoux F, Schultze JL, Murray PJ, Ochando J, Biswas SK. New insights into the multidimensional concept of macrophage ontogeny, activation and function. Nat Immunol. 2016;17:34–40.CrossRefPubMed

27.

Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS, et al. Atherosclerosis. Nat Rev Dis Primers. 2019;5:56. https://doi.org/10.1038/s41572-019-0106-z.CrossRefPubMed

28.

Björkbacka H. Atherosclerosis: cell biology and lipoproteins. Curr Opin Lipidol. 2015;26:67–9. https://doi.org/10.1097/MOL.0000000000000150.CrossRefPubMed

29.

Heusch G, Libby P, Gersh B, Yellon D, Böhm M, Lopaschuk G, et al. Cardiovascular remodelling in coronary artery disease and heart failure. Lancet. 2014;383:1933–43. https://doi.org/10.1016/S0140-6736(14)60107-0.CrossRefPubMed

30.

Pasterkamp G, den Ruijter HM, Libby P. Temporal shifts in clinical presentation and underlying mechanisms of atherosclerotic disease. Nat Rev Cardiol. 2017;14(1):21–9. https://doi.org/10.1038/nrcardio.2016.166.CrossRefPubMed

31.

Arbustini E, Dal Bello B, Morbini P, Burke AP, Bocciarelli M, Virmani R, et al. Plaque erosion is a major substrate for coronary thrombosis in acute myocardial infarction. Heart. 1999;82:269–72.CrossRefPubMed

32.

Kolodgie FD, Burke AP, Farb A, Weber DK, Kutys R, Virmani R, et al. Differential accumulation of proteoglycans and hyaluronan in culprit lesions: insights into plaque erosion. Arterioscler Thromb Vasc Biol. 2002;22:1642–8.CrossRefPubMed

33.

Franck G, Mawson T, Sausen G, Salinas M, Masson GS, Cole A, et al. Flow perturbation mediates neutrophil recruitment and potentiates endothelial injury via TLR2 in mice: implications for superficial erosion. Circ Res. 2017;121(1):31–42. https://doi.org/10.1161/CIRCRESAHA.117.310694.CrossRefPubMed

34.

Ketelhuth DF, Hansson GK. Adaptive response of T and B cells in atherosclerosis. Circ Res. 2016;118:668–78.CrossRef

35.

• Ridker PM, Lüscher TF. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J. 2014;35(27):1782–91. https://doi.org/10.1093/eurheartj/ehu203. Inflammation seems to play a major role in atherosclerotic plaque progression. The Authors explain the role of anti-inflammatory therapy in primary and secondary prevention of atherosclerotic cardiovascular events.

36.

Ridker PM. From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. Circ Res. 2016;118:145–56. https://doi.org/10.1161/CIRCRESAHA.115.306656.CrossRefPubMed

37.

• Mantovani A. Wandering pathways in the regulation of innate immunity and inflammation. J Autoimmun. 2017;85:1–5. https://doi.org/10.1016/j.jaut.2017.10.007. The report underlines the correlation between immunologic factors and progression of the atherosclerotic plaque.

38.

Bories GFP, Leitinger N. Macrophage metabolism in atherosclerosis. FEBS Lett. 2017;591:3042–60. https://doi.org/10.1002/1873-3468.12786.CrossRefPubMed

39.

Jaipersad AS, Lip GY, Silverman S, Shantsila E. The role of monocytes in angiogenesis and atherosclerosis. J Am Coll Cardiol. 2014;63:1–11. https://doi.org/10.1016/j.jacc.2013.09.019.CrossRefPubMed

40.

Ohta H, Wada H, Niwa T, Kirii H, Iwamoto N, Fujii H, et al. Disruption of tumor necrosis factor-alpha gene diminishes the development of atherosclerosis in ApoE-deficient mice. Atherosclerosis. 2005;180:11–7. https://doi.org/10.1016/j.atherosclerosis.2004.11.016.CrossRefPubMed

41.

Canault M, Peiretti F, Mueller C, Kopp F, Morange P, Rihs S, et al. Exclusive expression of transmembrane TNF-alpha in mice reduces the inflammatory response in early lipid lesions of aortic sinus. Atherosclerosis. 2004;172:211–8. https://doi.org/10.1016/j.atherosclerosis.2003.10.004.CrossRefPubMed

42.

Brånén L, Hovgaard L, Nitulescu M, Bengtsson E, Nilsson J, Jovinge S. Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol. 2004;24:2137–42. https://doi.org/10.1161/01.ATV.0000143933.20616.1.CrossRefPubMed

43.

Merhi-Soussi F, Kwak BR, Magne D, Chadjichristos C, Berti M, Pelli G, et al. Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. Cardiovasc Res. 2005;66:583–93. https://doi.org/10.1016/j.cardiores.2005.01.008.CrossRefPubMed

44.

Kirii H, Niwa T, Yamada Y, Wada H, Saito K, Iwakura Y, et al. Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 2003;23:656–60. https://doi.org/10.1161/01.ATV.0000064374.15232.C3.CrossRefPubMed

45.

Alexander MR, Moehle CW, Johnson JL, Yang Z, Lee JK, Jackson CL, et al. Genetic inactivation of IL-1 signaling enhances atherosclerotic plaque instability and reduces outward vessel remodeling in advanced atherosclerosis in mice. J Clin Invest. 2012;122:70–9. https://doi.org/10.1172/JCI43713.CrossRefPubMed

46.

Jonasson L, Holm J, Skalli O, Gabbiani G, Hansson GK. Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis. J Clin Invest. 1985;76:125–31.CrossRefPubMed

47.

Hansson GK, Jonasson L, Holm J. Claesson-WelshClass L II MHC antigen expression in the atherosclerotic plaque: smooth muscle cells express HLA-DR, HLA-DQ and the invariant gamma chain. Clin Exp Immunol. 1986;64:261–8.PubMed

48.

Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E, et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med. 2019;380:752–62. https://doi.org/10.1056/NEJMoa1809798.CrossRefPubMed

49.

Kyaw T, Tipping P, Bobik A, Toh BH. Opposing roles of B lymphocyte subsets in atherosclerosis. Autoimmunity. 2017;50:52–6. https://doi.org/10.1080/08916934.2017.1280669.CrossRefPubMed

50.

Nus M, Tsiantoulas D, Mallat Z. Plan B (-cell) in atherosclerosis. Eur J Pharmacol. 2017;816:76–81. https://doi.org/10.1016/j.ejphar.2017.09.002.CrossRefPubMed

51.

Pussinen PJ, Tuomisto K, Jousilahti P, Havulinna AS, Sundvall J. Salomaa V Endotoxemia, immune response to periodontal pathogens, and systemic inflammation associate with incident cardiovascular disease events. Arterioscler Thromb Vasc Biol. 2007;27:1433–9.CrossRefPubMed

52.

Andraws R, Berger JS. Brown DL Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials. JAMA. 2005;293:2641–7. https://doi.org/10.1001/jama.293.21.2641.CrossRefPubMed

53.

Martu O, Nicolaiciuc S, Solomon, et al. The evaluation of the C reactive protein levels in the context of the periodontal pathogens presence in cardiovascular risk patients. Rev Chim. 2017;68:1081–4.CrossRef

54.

Chi H, Messas E, Levine RA, Graves DT, Amar S. Interleukin-1 receptor signaling mediates atherosclerosis associated with bacterial exposure and/or a high-fat diet in a murine apolipoprotein E heterozygote model: pharmacotherapeutic implications. Circulation. 2004;110:1678–85.CrossRefPubMed

55.

Jonsson AL, Backhed F. Role of gut microbiota in atherosclerosis. Nat Rev Cardiol. 2017;14:79–87.CrossRefPubMed

56.

•• Libby P, Loscalzo J, Ridker PM, Farkouh ME, Hsue PY, Fuster V, et al. Inflammation, immunity, and infection in atherothrombosis: JACC review topic of the week. J Am Coll Cardiol. 2018;72:2071–81. https://doi.org/10.1016/j.jacc.2018.08.1043. Accurate review of the correlations between inflammation, infection, immunity and atherosclerosis.

57.

Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev. 2009;22:240–73.CrossRefPubMed

58.

Ivey KS, Edwards KM, Talbot HK. Respiratory syncytial virus and associations with cardiovascular disease in adults. J Am Coll Cardiol. 2018;71:1574–83.CrossRefPubMed

59.

Müller L, Di Benedetto S, Pawelec G. The immune system and its dysregulation with aging. Subcell Biochem. 2019;91:21–43. https://doi.org/10.1007/978-981-13-3681-2_2.CrossRefPubMed

60.

• Ridker PM. How common is residual inflammatory risk? Circ Res. 2017;120:617–9. https://doi.org/10.1161/CIRCRESAHA.116.310527. The paper underlines the fact that inflammatory parameters may allow a more appropriate medical therapy in patients who suffered from myocardial ischemia.

61.

Pradhan AD, Aday AW, Rose LM, Ridker PM. Residual inflammatory risk on treatment with pcsk9 inhibition and statin therapy. Circulation. 2018;138:141–9. https://doi.org/10.1161/CIRCULATIONAHA.118.034645.CrossRefPubMed

62.

•• Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377:111–21. https://doi.org/10.1056/NEJMoa1701719. Clonal hematopoiesis may represent an immunological unbalance more common in the elderly and it might represent a risk for atherosclerosis progression.

63.

Jaiswal S, Libby P. Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease. Nat Rev Cardiol. 2020;17:137–44. https://doi.org/10.1038/s41569-019-0247-5.CrossRefPubMed

64.

Khetarpal SA, Qamar A, Bick AG, Fuster JJ, Kathiresan S, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential reshapes age-related CVD: JACC review topic of the week. J Am Coll Cardiol. 2019;74:578–86. https://doi.org/10.1016/j.jacc.2019.05.045.CrossRefPubMed

65.

Qi YX, Jiang J, Jiang XH, Wang XD, Ji SY, Han Y, et al. PDGF-BB and TGF-{beta}1 on cross-talk between endothelial and smooth muscle cells in vascular remodeling induced by low shear stress. Proc Natl Acad Sci U S A. 2011;108:1908–13. https://doi.org/10.1073/pnas.1019219108.CrossRefPubMed

66.

Conway DE, Schwartz MA. Flow-dependent cellular mechanotransduction in atherosclerosis. J Cell Sci. 2013;126:5101–9. https://doi.org/10.1242/jcs.138313.CrossRefPubMed

67.

Samady H, Eshtehardi P, McDaniel MC, Suo J, Dhawan SS, Maynard C, et al. Coronary artery wall shear stress is associated with progression and transformation of atherosclerotic plaque and arterial remodeling in patients with coronary artery disease. Circulation. 2011;124:779–88. https://doi.org/10.1161/CIRCULATIONAHA.111.021824.

68.

Augst AD, Ariff BD, SA MGT, Xu XY, Hughes AD. Analysis of complex flow and the relationship between blood pressure, wall shear stress, and intima-media thickness in the human carotid artery. Am J Physiol Heart Circ. 2007;293:H1031–7. https://doi.org/10.1152/ajpheart.00989.2006.CrossRef

69.

Thondapu V, Bourantas CV, Foin N, Jang IK, Serruys PW, Barlis P. Biomechanical stress in coronary atherosclerosis: emerging insights from computational modelling. Eur Heart J. 2017;38(2):81–92. https://doi.org/10.1093/eurheartj/ehv689.CrossRefPubMed

70.

Hodis S, Zamir M. Mechanical events within the arterial wall under the forces of pulsatile flow: a review. J Mech Behav Biomed Mater. 2011;4:1595–602. https://doi.org/10.1016/j.jmbbm.2011.01.005.CrossRefPubMed

71.

Sterpetti AV, Cucina A, Morena A, Di Donna S, D'Angelo LS, Cavalarro A, et al. Shear stress increases the release of Interleukin 1 and 6 by aortic endothelial cells. Surgery. 1993;114:911–4.PubMed

72.

Sterpetti AV, Cucina A, Borrelli V, Ventura M. Inflammation and myointimal hyperplasia. Correlation with hemodynamic forces. Vasc Pharmacol. 2019;117:1–6. https://doi.org/10.1016/j.vph.2017.06.001.CrossRef

73.

Sterpetti AV, Cucina A, D'Angelo LS, Cardillo B, Cavallaro A. Shear stress modulates the proliferation rate, protein synthesis, and mitogenic activity of arterial smooth muscle cells. Surgery. 1993;113:691–9.PubMed

74.

Malek AM, Alper SL, Izumo S. Hemodynamic shear stress and its role in atherosclerosis. JAMA. 1999;282:2035–42.CrossRefPubMed

75.

Wang KC, Yeh YT, Nguyen P, Limqueco E, Lopez J, Thorossian S, et al. Flow-dependent YAP/TAZ activities regulate endothelial phenotypes and atherosclerosis. Proc Natl Acad Sci U S A. 2016;113:11525–30.CrossRefPubMed

76.

Sterpetti AV, Lepidi S, Borrelli V, et al. Growth factors and experimental arterial grafts. J Vasc Surg. 2016;64:1444–9. https://doi.org/10.1016/j.jvs.2015.07.091.CrossRefPubMed

77.

Wang S, Vafai K. Analysis of Low Density Lipoprotein (LDL) Transport Within a Curved Artery. Ann Biomed Eng. 2015;43:1571–84. https://doi.org/10.1007/s10439-014-1219-x.CrossRefPubMed

78.

Mundi S, Massaro M, Scoditti E, Carluccio MA, van Hinsbergh VWM, De Caterina R. Endothelial permeability, LDL deposition, and cardiovascular risk factors-a review. Cardiovasc Res. 2018;114:35–52. https://doi.org/10.1093/cvr/cvx226.CrossRefPubMed

79.

Raggi P, Genest J, Giles JT, Rayner KJ, Dwivedi G, Beanlands RS, et al. Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions. Atherosclerosis. 2018;276:98–108. https://doi.org/10.1016/j.atherosclerosis.2018.07.014.CrossRef

80.

Calcagno C, Fayad ZA. Raggi P Plaque microvascularization and permeability: Key players in atherogenesis and plaque rupture. Atherosclerosis. 2017;263:320–1. https://doi.org/10.1016/j.atherosclerosis.2017.06.915.CrossRefPubMed

81.

Yahagi K, Kolodgie FD, Lutter C, Mori H, Romero ME, Virmani R. Pathology of human coronary and carotid artery atherosclerosis and vascular calcification in diabetes mellitus. Arterioscler Thromb Vasc Biol. 2017;37:191–204.CrossRefPubMed

82.

Otsuka F, Kramer MC, Woudstra P, Yahagi K, Ladich E, Finn AV, et al. Natural progression of atherosclerosis from pathologic intimal thickening to late fibroatheroma in human coronary arteries: a pathology study. Atherosclerosis. 2015;241:772–82. https://doi.org/10.1016/j.atherosclerosis.2015.05.011.CrossRefPubMed

83.

Kobayashi Y, Kitahara H, Tanaka S, Okada K, Kimura T, Ikeno F, et al. Quantitative precision of optical frequency domain imaging: direct comparison with frequency domain optical coherence tomography and intravascular ultrasound. Cardiovasc Interv Ther. 2016;31:79–88. https://doi.org/10.1007/s12928-015-0349-x.CrossRefPubMed

84.

Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, et al. PROSPECT investigators. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364:226–35. https://doi.org/10.1056/NEJMoa1002358.CrossRefPubMed

85.

• Chang HJ, Lin FY, Lee SE, Andreini D, Bax J, Cademartiri F, et al. Coronary atherosclerotic precursors of acute coronary syndromes. J Am Coll Cardiol. 2018;71:2511–22. https://doi.org/10.1016/j.jacc.2018.02.079. Detailed description of the risk factors for acute coronary syndrome.

86.

Partida RA, Libby P, Crea F, Jang IK. Plaque erosion: a new in vivo diagnosis and a potential major shift in the management of patients with acute coronary syndromes. Eur Heart J. 2018;39(22):2070–6. https://doi.org/10.1093/eurheartj/ehx786.CrossRefPubMed

87.

• Crea F, Libby P. Acute coronary syndromes: the way forward from mechanisms to precision treatment. Circulation. 2017;136:1155–66. https://doi.org/10.1161/CIRCULATIONAHA.117.029870. The paper underlines the attention to the specific clinical characteristics of patients with acute coronary syndrome, addressing the importance of a personalized therapy.

88.

Lanza GA, Crea F. Overview of Management of Myocardial Ischemia: a Mechanistic-Based Approach. Cardiovasc Drugs Ther. 2016;30:341–9. https://doi.org/10.1007/s10557-016-6662-5.CrossRefPubMed

89.

Hu S, Yonetsu T, Jia H, Karanasos A, Aguirre AD, Tian J, et al. Residual thrombus pattern in patients with ST-segment elevation myocardial infarction caused by plaque erosion versus plaque rupture after successful fibrinolysis: an optical coherence tomography study. J Am Coll Cardiol. 2014;63:1336–8. https://doi.org/10.1016/j.jacc.2013.11.025.CrossRefPubMed

90.

Timmins LH, Molony DS, Eshtehardi P, McDaniel MC, Oshinski JN, Giddens DP, et al. Oscillatory wall shear stress is a dominant flow characteristic affecting lesion progression patterns and plaque vulnerability in patients with coronary artery disease. J R Soc Interface. 2017;14:20160972. https://doi.org/10.1098/rsif.2016.0972.CrossRefPubMed

91.

Saia F, Komukai K, Capodanno D, Sirbu V, Musumeci G, Boccuzzi G, et al. Eroded versus ruptured plaques at the culprit site of STEMI: in vivo pathophysiological features and response to primary PCI. JACC Cardiovasc Imaging. 2015;8:566–75. https://doi.org/10.1016/j.jcmg.2015.01.018.CrossRefPubMed

92.

• Jolly SS, James S, Džavík V, Cairns JA, Mahmoud KD, Zijlstra F, et al. Thrombus aspiration in ST-segment-elevation myocardial infarction: an individual patient meta-analysis: thrombectomy trialists collaboration. Circulation. 2017;135:143–52. https://doi.org/10.1161/CIRCULATIONAHA.116.025371. Aspirating coronary thrombi in patients with acute coronary syndrome, the Authors found significant pathological differences which were correlated with clinical outcomes.

93.

• Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388:2532–61. One of the first reviews which demonstrated a major role for statins in primary and secondary prevention of atherosclerotic cardiovascular events.

94.

Ridker PM, Danielson E, Fonseca FAH, Genest J, Gottto AM, Kastelein JJP, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.CrossRefPubMed

95.

• Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392:1036–46. https://doi.org/10.1016/S0140-6736(18)31924-X. A randomized trial which did not show significant clinical positive effects of low dose aspirin. There was a small reduction in the rate of cardiovascular events, but there was an increased rate of side effects, mainly bleeding (ARRIVE TRIAL).

96.

•• McNeil JJ, Wolfe R, Woods RL, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018;379:1509–18. Similar conclusions to the previous report, considering only healthy elderly.

97.

•• ASCEND Study Collaborative Group, Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379:1529–39. https://doi.org/10.1056/NEJMoa1804988. Similar conclusions to the previous reports, considering patients with diabetes mellitus (ASCEND TRIAL).

98.

•• Ridker PM. Should aspirin be used for primary prevention in the post-statin era? N Engl J Med. 2018;379:1572–4. https://doi.org/10.1056/NEJMe1812000. Accurate analysis of the results of several randomized prospective trials about the usefulness of low dose aspirin in the prevention of cardiovascular events. Does low dose aspirin prevention have a role in the era of statins therapy?

99.

•• Ridker PM, Everett BM, Thuren T, et al. CANTOS Trial group. Anti inflammatory therapy with canakinumab for atherosclerosis disease. N Engl J Med. 2017;377:1119–31. Prospective randomized trial: patients with previous myocardial ischemia had either optimal standard therapy or the same therapy plus a selective anti-inflammatory inhibitors able to neutralize the action of Interleukin 1 beta. The inhibition of IL 1 beta reduced significantly future cardiovascular events, namely in patients with increased systemic levels of C Reactive Protein.

100.

CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329–1339

101.

Bhatt DL, Fox KAA, Hacke W, Berger PB, Black HR, Boden WE, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706–17.CrossRefPubMed

102.

Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791–800.CrossRefPubMed

103.

• Hiatt WR, Fowkes FGR, Heizer G, Berger JS, Baumgartner I, Held P, et al. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med. 2017;376:32–40. Aggressive anti-inflammatory and anti-platelet therapy reduces cardiovascular events, but there is increased risk for bleeding.

104.

Anand SS, Yusuf S. Oral anticoagulants in patients with coronary artery disease. J Am Coll Cardiol. 2003;41(Suppl S):62S–9S.CrossRefPubMed

105.

The Warfarin Antiplatelet Vascular Evaluation Trial Investigators. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med. 2007;357:217–27.CrossRef

106.

Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366:1404–13.CrossRefPubMed

107.

• Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017;377:1319–30. https://doi.org/10.1056/NEJMoa1709118. Aggressive anti-inflammatory and anti-platelet therapy reduces cardiovascular events, but there is increased risk for bleeding.

108.

Everett BM, MacFadyen JG, Thuren T, Libby P, Glynn RJ, Ridker PM. Inhibition of interleukin-1β and reduction in atherothrombotic cardiovascular Events in the CANTOS trial. J Am Coll Cardiol. 2020;76(14):1660–70. https://doi.org/10.1016/j.jacc.2020.08.011.

109.

Garratt KN, Weaver WD, Jenkins RG, Pow TK, Mauri L, Kereiakes DJ, et al. Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberté paclitaxel-eluting coronary stent placement. Circulation. 2015;131:62–73. https://doi.org/10.1161/CIRCULATIONAHA.114.013570.CrossRefPubMed

110.

Ullery BW, Tran K, Itoga N, Casey K, Dalman RL, et al. Safety and efficacy of antiplatelet/anticoagulation regimens after Viabahn stent graft treatment for femoropopliteal occlusive disease. J Vasc Surg. 2015;61:1479–88. https://doi.org/10.1016/j.jvs.2014.12.062.CrossRefPubMed

111.

• Yeh RW, Kereiakes DJ, Steg PG, Windecker S, Rinaldi MJ, Gershlick AH, et al. Benefits and risks of extended duration dual antiplatelet therapy after pci in patients with and without acute myocardial infarction. J Am Coll Cardiol. 2015;65:2211–21. https://doi.org/10.1016/j.jacc.2015.03.003. Aggressive anti-inflammatory and anti-platelet therapy reduces cardiovascular events, but there is increased risk for bleeding.

112.

Morton AC, Rothman AM, Greenwood JP, Gunn J, Chase A, Clarke B, et al. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study. Eur Heart J. 2015;36:377–84. https://doi.org/10.1093/eurheartj/ehu272.CrossRefPubMed

113.

Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 (PROVE IT-TIMI 22) investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20–8. https://doi.org/10.1056/NEJMoa042378.CrossRefPubMed

114.

Bohula EA, Giugliano RP, Cannon CP, Zhou J, Murphy SA, White JA, et al. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE IT. Circulation. 2015;132:1224–33. https://doi.org/10.1161/CIRCULATIONAHA.115.018381.CrossRefPubMed

115.

• Lu Y, Zhou S, Dreyer RP, Spatz ES, Geda M, Lorenze NP, et al. Sex differences in inflammatory markers and health status among young adults with acute myocardial infarction: Results from the VIRGO study. Circ Cardiovasc Qual Outcomes. 2017;10:e003470. https://doi.org/10.1161/CIRCOUTCOMES.116.003470. The VIRGO study reports how is common the possibility of a systemic inflammatory condition in patients who suffered from myocardial ischemia.

116.

Higham J, Kang JY, Majeed A. Recent trends in admissions and mortality due to peptic ulcer in England: increasing frequency of haemorrhage among older subjects. Gut. 2002;50:460–4.CrossRefPubMed

117.

Sterpetti AV, Cavallari N, Allegrucci P, et al. Seasonal variation in the incidence of ruptured abdominal aortic aneurysms. J R Coll Edinb. 1995;40:14–5.

118.

• Taylor CA, Bell JM, Breiding MJ, Xu L. Traumatic brain injury-related emergency department visits, hospitalizations, and deaths - United States, 2007 and 2013. MMWR Surveill Summ. 2017;66:1–16. https://doi.org/10.15585/mmwr.ss6609a1. There is evidence of increased mortality in the elderly from head trauma. Is this fact related to the diffuse prescription of aspirin to elderly patients?

Title: Inflammatory Cytokines and Atherosclerotic Plaque Progression. Therapeutic Implications
Author: Antonio V Sterpetti
Publication date: 01-12-2020
Publisher: Springer US
Keywords: Arterial Occlusive Disease
Cytokines
Growth Factors
Growth Factors
Published in: Current Atherosclerosis Reports / Issue 12/2020
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI: https://doi.org/10.1007/s11883-020-00891-3

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Home
Congress Coverage
Clinical Collections
- Advances in Alzheimer’s
About Springer Medicine
Key Specialties